NCT03717298 is a Phase 2 clinical trial of Ocoxin-Viusid® in Adenocarcinoma of the Pancreas, sponsored by Catalysis SL.

Who is sponsoring NCT03717298?

NCT03717298 is sponsored by Catalysis SL.

What drugs are being tested in NCT03717298?

Interventions in NCT03717298: Ocoxin-Viusid®.

What condition does NCT03717298 study?

NCT03717298 studies Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases.

Is NCT03717298 still recruiting?

NCT03717298 is currently completed. Last updated 28 March 2023.

Last reviewed 2023-03-28 · How we verify

NCT03717298

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Completed Phase 2 Last updated 28 March 2023

What this trial tests

Phase 2 trial testing Ocoxin-Viusid® in Adenocarcinoma of the Pancreas in 30 participants. Completed in 20 January 2023.

Timeline

30 October 2018

Primary endpoint
1 December 2022

20 January 2023

Quick facts

Lead sponsor	Catalysis SL
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	30
Start date	30 October 2018
Primary completion	1 December 2022
Estimated completion	20 January 2023
Sites	1 location across Cuba

Drugs / interventions tested

Ocoxin-Viusid®

Conditions studied

Adenocarcinoma of the Pancreas — all drugs for Adenocarcinoma of the Pancreas →
Pancreatic Cancer — all drugs for Pancreatic Cancer →
Advanced Cancer — all drugs for Advanced Cancer →
Digestive System Neoplasms — all drugs for Digestive System Neoplasms →

Sponsor

Catalysis SL — full company profile →

Who can join

18 and older, any sex, with Adenocarcinoma of the Pancreas or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid® is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "Hermanos Ameijeiras" Surgical Clinical Hospital. Phase II clinical trial, open, multicenter, nonrandomized.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?
Brandi G, Turroni S, McAllister F, Frega G. · · 2021 · cited 15× · PMID 34576078 · DOI 10.3390/ijms22189914
Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit?
Ren L, Mota Reyes C, Friess H, Demir IE. · · 2020 · cited 8× · PMID 32776259 · DOI 10.1007/s00423-020-01946-4

Verify or expand the search:

Other trials of Ocoxin-Viusid®

Trials testing the same drug.

NCT03549494 — Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction · Phase 2 · completed

Other recruiting trials for Adenocarcinoma of the Pancreas

Currently open trials in the same condition.

NCT06582342 — Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients? · recruiting
NCT05116072 — Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula · Phase 1, PHASE2 · recruiting

Other Catalysis SL trials

Trials by the same sponsor.

NCT07179237 — Efficacy of Carminal in Helicobacter Pylori Gastritis · Phase 2 · recruiting
NCT06363201 — Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumour · NA · not yet recruiting
NCT05916911 — Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In P · Phase 4 · unknown
NCT06496087 — Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment · NA · completed
NCT06361992 — Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03717298 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Catalysis SL
Last refreshed: 28 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717298.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing